Please login to get additional information, such as OSPEMIFENE development phases.

Not a member yet? Sign Up here, it's free!

Ophena is a new selective estrogen receptor modulator (SERM) for menopausal-related symptoms, initially being developed for the treatment of vaginal atrophy.

Ophena is differentiated from hormone therapies such as estrogen. Ophena is a next generation SERM (selective estrogen receptor modulator) that selectively binds to estrogen receptors and either stimulates or blocks estrogen's activity in different tissue types. SERMs in development have been shown to mimic estrogen's beneficial action in bone tissue but do not stimulate estrogen's harmful effects in the breast and uterus which increase the risk of cancer.
Drug information
Highest Dev Status Phase 3
Therapeutic AreaEndocrine
Potential Indications Please Login
Identified Action Mechanisms1
Literature NCBI